Drug rash with eosinophilia and systemic symptoms (DRESS) 
Introduction

Drug hypersensitivity syndrome is defined as the clinical triad of fever, rash, and internal organ involvement due to drug exposure (1). Other groups have used the term 'drug rash with eosinophilia and systemic symptoms (DRESS)' to describe the same syndrome (2). A Japanese consensus group proposed the term 'drug-induced hypersensitivity syndrome (DIHS)' (3). The role of herpesvirus including human herpesvirus 6 (HHV-6) in the development of this adverse drug reaction is well recognized (4-6). The presence of HHV-6 DNA in skin lesions and the similarity between DRESS/DIHS and severe HHV-6 primary infection or reactivation suggest that the virus may itself be responsible for the skin lesions and some of the visceral involvement (5). It is probable that the culprit drug induces a state of immunosuppression that favors HHV-6 reactivation (7)
. Shiohara et al. (3) T a b l e 1 . L a b o r a t o r y F i n d i n g s o n Ad mi s s i o n 
drugs, late onset, clinical similarity to mononucleosis-like syndrome and a prolonged course. The syndrome typically develops 2-6 weeks after the initiation of drug administration. The initial signs are fever and maculopapular eruptions. Lymphadenopathy, hepatitis, renal dysfunction and hematological abnormalities are observed to various degrees (4). The mortality from DIHS/DRESS is approximately 10% to 20% and is associated with the degree of hepatic or renal involvement (6, 9). Studies on a large series of patients in Japan revealed that the drugs responsible for the development of DIHS/DRESS are limited to eight drugs in the vast majority of patients: they include carbamazepine, phenytoin, phenobarbital, zonisamide, mexiletine, dapsone, sulfasalazine and allopurionol (3).
Among these drugs, carbamazepine (10) , dapsone (11) and allopurionol (12) (13) 
reported that drug-specific T cells are activated locally and orchestrate a local inflammation via secretion of various cytokines in acute drug-induced interstitial nephritis. In DIHS/DRESS, activation of drug-specific T cells is considered to play an indispensable role in the multiorgan system reaction (14). Sixty mg of prednisolone divided into three doses was started the day before the renal biopsy. Peripheral eosinophils decreased from 11,000/μL to 456/μL on the day of renal biopsy. Infiltration of eosinophils in the interstitium of the kidney may also have been affected by prednisolone.
Proteinuria consisting of albuminuria of over 1 g/day was observed on the first and second hospital day. This period corresponded with the time of oliguria. After the third hospital day, the protein level in the urine decreased rapidly and was not detected on day 7. Urine volume also began to increase after the third hospital day. The cytokine profile in DIHS/DRESS is dynamic (15) . Perhaps humoral factors other than cytokines might also be dynamic and it is speculated that the levels of some humoral factors promoting protein permeability of the capillary wall and decreasing glomerular filtration were increased in the circulating blood during this period. As another possibility, the evaluation of proteinuria by gram per 1 gram creatinine might be overestimated due to oliguria on admission.
Patients with DIHS show several immune system defects at the onset of DIHS including remarkable reductions in serum IgG levels and circulating B-cell counts, which allow reactivation of herpesviruses (16) . The decreased level of IgG on admission in the present case was compatible with this characteristic course of DIHS. Some anticonvulsants act through a direct immunosuppressive effect on B cells and subsequent decreased immunoglobulin production (17) . In the present case, zonisamide had been prescribed and might have contributed to the immunosuppressive effect.
The pathomechanisms of DRESS/DIHS remain largely
F i g u r e 2 . L i g h t mi c r o s c o p y o f t h e r e n a l b i o p s y s p e c i me n o b t a i n e d o n t h e 5 t h h o s p i t a l d a y ( a ) Gl o me r u l i s h o we d mi n o r a b n o r ma l i t y . T h e r e wa s i n f i l t r a t i o n o f mo n o n u c l e a r c e l l s a n d e o s i n o p h i l s a r o u n d a g l o me r u l u s . Ar r o w s h o ws a n e o s i n o p h i l . ( He ma t o x y l i n a n d E o s i n s t a i n i n g × 2 0 0 ) . ( b ) T ub u l a r e p i t h e l i a l c e l l s we r e s wo l l e n a n d d e n e n e r a t i n g . Ar r o w s h o ws a n e o s i n o p h i l . B o l d a r r o w s h o ws t u b u l i t i s . ( He ma t o x y l i n a n d E o s i n s t a i n i n g × 2 0 0 ) . ( c ) I n t e r s t i t i a l e d e ma a n d p a t c h y i n f i l t r a t i o n o f mo n o n u c l e a r c e l l s a n d e o s i n o p h i l s a r e o b s e r v e d . ( P AM-He ma t o x y l i n a n d E o s i n s t a i n i n g × 5 0 ) .
F i g u r e 3 . Cl i n i c a l c o u r s e a n d t r e a t me n t . (18, 19 (20) , cyclosporine (21) , and plasmapheresis (20) .
unknown. As to the drug-related pathology of DIHS, drugspecific T cells or toxic oxidative metabolites of parent drugs have been hypothesized
In conclusion, hypersensitivity syndrome with acute kidney injury may occur with zonisamide therapy. Early recognition of this syndrome and prompt corticosteroid therapy lead to improved prognosis.
